Login Register Cart 0
Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Science-based Ethnic Bridging in Drug Development; Review of Recent Precedence and Suggested Steps Forward

Author(s): Ewoud-Jan van Hoogdalem*, John P. Jones III, John Constant and Meguru Achira

Volume 14, Issue 3, 2019

Page: [197 - 207] Pages: 11

DOI: 10.2174/1574884714666190408125206

Abstract

Background: Exposure, safety and/or efficacy of drugs are subject to potential differences between human races or ethnicities, as acknowledged by regulatory guidance and by label texts of various, but not all approved drugs.

Objective: The objective of the present review was to assess recent regulatory precedence on drug use and race or ethnicity, with the goal of identifying opportunities for increasing the informative value of clinical ethnic or racial bridging in drug development.

Methods: Recently, (January 2014-July 2018) FDA approved drug product label texts and approval packages were reviewed for claims, comments and underlying data on use of the product in specific ethnic or racial groups.

Results: Among the 266 FDA-approved products, no product with unambiguous race- or ethnicity specific dosing instructions was retrieved. A small majority (55%) was approved with a claim or comment on race or ethnicity, and of these, a large majority (87%) was based on population pharmacokinetic data analysis. Statements were often related to incidence of a genotype for drug metabolizing enzyme or for other risk factors, or were related to body weight. Absence of clinically relevant exposure differences were often justified in terms of exposure ratios that notably exceeded the typical 0.80-1.25 no-effect boundary.

Conclusions: Recent precedence reflected a pragmatic, descriptive approach of racial or ethnic bridging, apparently meeting current regulatory expectations, whilst not resulting in strict guidance to prescribers. We recommend further work on defining the objectives of bridging studies, as well as criteria for their design and data analysis. Regarding the latter, we recommend investigating the value of prospectively defined tests for similarity with appropriate follow-up analysis in the case where the test has failed.

Keywords: Race, ethnicity, product label, clinical drug development, tacrolimus, antihypertensives.

« Previous Next »
Graphical Abstract

[1]
Chen ML. Ethnic or racial differences revisited: Impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006; 45(10): 957-64.
[http://dx.doi.org/10.2165/00003088-200645100-00001] [PMID: 16984210]
[2]
Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2013; 52(12): 1085-100.
[http://dx.doi.org/10.1007/s40262-013-0089-y] [PMID: 23818090]
[3]
Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: Review of recently approved drugs. Clin Pharmacol Ther 2015; 97(3): 263-73.
[http://dx.doi.org/10.1002/cpt.61] [PMID: 25669658]
[4]
Shah RR, Gaedigk A. Precision medicine: Does ethnicity information complement genotype-based prescribing decisions? Ther Adv Drug Saf 2018; 9(1): 45-62.
[http://dx.doi.org/10.1177/2042098617743393] [PMID: 29318005]
[5]
Li R, Barton HA. Explaining ethnic variability of transporter substrate pharmacokinetics in healthy Asian and Caucasian subjects with allele frequencies of OATP1B1 and BCRP: A mechanistic modeling analysis. Clin Pharmacokinet 2018; 57(4): 491-503.
[http://dx.doi.org/10.1007/s40262-017-0568-7] [PMID: 28653144]
[6]
Birmingham BK, Bujac SR, Elsby R, et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: A class effect? Eur J Clin Pharmacol 2015; 71(3): 341-55.
[http://dx.doi.org/10.1007/s00228-014-1801-z] [PMID: 25673568]
[7]
Brewster LM, van Montfrans GA, Oehlers GP, Seedat YK. Systematic review: Antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med 2016; 11(3): 355-74.
[http://dx.doi.org/10.1007/s11739-016-1422-x] [PMID: 27026378]
[8]
Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000; 68(5): 478-86.
[http://dx.doi.org/10.1067/mcp.2000.111255] [PMID: 11103750]
[9]
Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: A perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42(12): 701-18.
[http://dx.doi.org/10.5414/CPP42701] [PMID: 15624287]
[10]
Sanghavi K, Brundage RC, Miller MB, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J 2017; 17(1): 61-8.
[http://dx.doi.org/10.1038/tpj.2015.87] [PMID: 26667830]
[11]
Dean L. Esomeprazole Therapy and CYP2C19 Genotype 2012 Oct 1 Medical Genetics Summaries Bethesda, MD. National Center for Biotechnology Information (US) 2012. Available at .https://www.ncbi.nlm.nih.gov/books/NBK100896/ [Accessed September 5, 2018]
[12]
Feng S, Cleary Y, Parrott N, et al. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. Eur J Clin Pharmacol 2015; 71(5): 617-24.
[http://dx.doi.org/10.1007/s00228-015-1834-y] [PMID: 25801493]
[13]
Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60(2): 157-67.
[http://dx.doi.org/10.1016/S0009-9236(96)90131-9] [PMID: 8823233]
[14]
Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8(3): 195-201.
[http://dx.doi.org/10.1097/00004714-198806000-00008] [PMID: 3379143]
[15]
Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52(3): 265-71.
[http://dx.doi.org/10.1046/j.0306-5251.2001.01437.x] [PMID: 11560558]
[16]
Zhang-Wong J, Beiser M, Zipursky RB, Bean G. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998; 81(3): 333-9.
[http://dx.doi.org/10.1016/S0165-1781(98)00114-0] [PMID: 9925184]
[17]
Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996; 42(3): 339-46.
[http://dx.doi.org/10.1046/j.1365-2125.1996.03879.x] [PMID: 8877025]
[18]
Rasool AH, Rahman AR, Ismail R, et al. Ethnic differences in response to non-selective beta-blockade among racial groups in Malaysia. Int J Clin Pharmacol Ther 2000; 38(5): 260-9.
[http://dx.doi.org/10.5414/CPP38260] [PMID: 10839470]
[19]
Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol 2013; 149(9): 1025-32.
[http://dx.doi.org/10.1001/jamadermatol.2013.4114] [PMID: 23884208]
[20]
Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55(4): 496-506.
[http://dx.doi.org/10.1111/epi.12564] [PMID: 24597466]
[21]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline ethnic factors in the acceptability of foreign clinical data E5 (R1) 1998. Current Step 4 version dated 5 February 1998.
[22]
Food and Drug Administration. Guidance for Industry E5 – Ethnic Factors in the Acceptability of Foreign Clinical Data. Questions and Answers. Revision 1. September. 2006.
[23]
Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther 2011; 42: 11-20.
[http://dx.doi.org/10.3999/jscpt.42.11]
[24]
Promacta® (eltrombopag) product label text. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022291s020,207027s005lbl.pdf
[25]
Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berl) 1988; 96(3): 365-9.
[http://dx.doi.org/10.1007/BF00216063] [PMID: 3146770]
[26]
He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 2002; 58(1): 15-8.
[http://dx.doi.org/10.1007/s00228-002-0425-x] [PMID: 11956668]
[27]
Matic M, de Wildt SN, Tibboel D, van Schaik RHN. Analgesia and opioids: A pharmacogenetics shortlist for implementation in clinical practice. Clin Chem 2017; 63(7): 1204-13.
[http://dx.doi.org/10.1373/clinchem.2016.264986] [PMID: 28637770]
[28]
Sugiyama Y, Maeda K, Toshimoto K. Is ethnic variability in the exposure to rosuvastatin explained only by genetic polymorphisms in OATP1B1 and BCRP or should the contribution of intrinsic ethnic differences in OATP1B1 be considered? J Pharm Sci 2017; 106(9): 2227-30.
[http://dx.doi.org/10.1016/j.xphs.2017.04.074] [PMID: 28479351]
[29]
Fujiwara Y, Hamada A, Mizugaki H, et al. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci 2016; 107(8): 1117-23.
[http://dx.doi.org/10.1111/cas.12983] [PMID: 27270784]
[30]
Rayner BL, Spence JD. Hypertension in blacks: Insights from Africa. J Hypertens 2017; 35(2): 234-9.
[http://dx.doi.org/10.1097/HJH.0000000000001171] [PMID: 27841780]
[31]
Do AN, Lynch AI, Claas SA, et al. The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens 2016; 30(9): 549-54.
[http://dx.doi.org/10.1038/jhh.2015.121] [PMID: 26791477]
[32]
Gong Y, McDonough CW, Beitelshees AL, et al. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens 2015; 33(11): 2278-85.
[http://dx.doi.org/10.1097/HJH.0000000000000714] [PMID: 26425837]
[33]
Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother 2018; 52(11): 1143-51.
[http://dx.doi.org/10.1177/1060028018779082] [PMID: 29808707]
[34]
Morin-Ben Abdallah S, Hirsh V. Epidermal growth factor receptor tyrosine kinase inhibitors in treatment of metastatic non-small cell lung cancer, with a focus on afatinib. Front Oncol 2017; 7: 97.
[http://dx.doi.org/10.3389/fonc.2017.00097] [PMID: 28560182]
[35]
Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006; 24(14): 2158-63.
[http://dx.doi.org/10.1200/JCO.2006.06.5961] [PMID: 16682734]
[36]
Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20): 2049-57.
[http://dx.doi.org/10.1056/NEJMoa042934] [PMID: 15533851]
[37]
Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. Am J Cardiol 2014; 114(1): 151-9.
[http://dx.doi.org/10.1016/j.amjcard.2014.04.018] [PMID: 24846808]
[38]
Ziaeian B, Fonarow GC, Heidenreich PA. Clinical Effectiveness of hydralazine-isosorbide dinitrate in African-American patients with heart failure. JACC Heart Fail 2017; 5(9): 632-9.
[http://dx.doi.org/10.1016/j.jchf.2017.04.008] [PMID: 28711446]
[39]
Pharm GKB. Available at: www.pharmgkb.org/page/cyp2c19RefMaterials [Accessed September 11, 2018].
[40]
https://www. accessdata.fda.gov/drugsatfda_docs/label/2017/205123 s014lbl.pdf [Accessed September 5, 2018].
[41]
Quigley JM, Bryden PA, Scott DA, Kuwabara H, Cerri K. Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis. Hepatol Res 2015; 45(10): E89-98.
[http://dx.doi.org/10.1111/hepr.12467] [PMID: 25559771]
[42]
CenterWatch: Clinical Research and Drug Information. www.centerwatch.com/drug-information/fda-approved-drugs
[43]
Drugs@FDA: FDA Approved Drug Products. Available at: www.accessdata.fda.gov/scripts/cder/daf/
[44]
Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 2010; 87(6): 714-20.
[http://dx.doi.org/10.1038/clpt.2010.31] [PMID: 20410879]
[45]
Fukunaga S, Kusama M, Arnold FL, Ono S. Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 2011; 51(8): 1237-40.
[http://dx.doi.org/10.1177/0091270010381500] [PMID: 21209235]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy